This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet - Top-Institutions - MDSpire

This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet

Lilly moves to acquire Kelonia, plus gene therapy for deafness approved

  • April 27, 2026

  • 6 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Cell Therapy
    • Hematologic Malignancies
    • Gene Therapy

  • #2

    University of Pennsylvania
    University of Pennsylvania

    Philadelphia, PA

    Key Differentiators

    • Gene Therapy
    • Immunotherapy
    • Cell Therapy

  • #3

    National Cancer Institute (NCI)
    National Cancer Institute (NCI)

    Bethesda, MD

    Key Differentiators

    • Cancer Immunotherapy
    • Gene Therapy
    • Cell Therapy

  • #4

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Gene Therapy
    • Cell Therapy
    • Immuno-oncology

  • #5

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Cell Therapy
    • Gene Therapy
    • Hematologic Malignancies

Original Source(s)

This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet

  • April 27, 2026

Related Content

Comprehensive Epilepsy Program marks 100th responsive neurostimulation procedure

UCI Health physicians have completed their 100th procedure using the RNS® System.

  • April 8, 2026

  • 1 min
Baptist Health Foundation Receives $2M Gift to Establish Endowed Chair at Baptist Health Miami Neuroscience Institute

Baptist Health Foundation announced that it has received a $2 million donation from Anthony and Joyce Esernia to establish a new endowed chair at Baptist Health Miami Neuroscience Institute.

  • May 1, 2026

  • 5 min
GLP-1 Drugs Linked to GI Effects, Uncertain Signals

Umbrella review evaluates over 1,700 trials to assess noncardiometabolic outcomes beyond weight and glycemic effects.